Helix BioPharma Corp. saw a notable increase in its stock price, reflecting positive investor sentiment.
In yesterday's trading session, Helix BioPharma Corp. (HBP.TO) experienced a gain of 3.16%, closing at CA$0.98. This uptick is a welcome development for investors, especially considering the company's recent activities and financial maneuvers.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$72.56M
52W high
$5.40
52W low
$0.91
1W change
-13.64%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 163.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+163.2% Upside
Current Price
C$0.95
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
107.8%
Annualized
90-Day Vol
76.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.79
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.90 | C$0.62 – C$1.30 |
| 60 trading days | C$0.84 | C$0.50 – C$1.43 |
| 90 trading days | C$0.79 | C$0.42 – C$1.51 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may find optimism in Helix BioPharma's recent capital raising efforts and strategic initiatives, which could bolster its future growth potential.
Market Cap at CA$74.85 Million
With a market cap of CA$74.85 million, Helix BioPharma remains a small-cap player in the biotech sector, often subject to volatility and investor sentiment.
Bull case
The recent capital raising agreement with Kerentech Consulting Ltd. positions Helix BioPharma to advance its therapeutic programs. This could enhance its market standing and boost investor confidence.
Bear case
Despite the positive movement, Helix BioPharma has reported significant net losses, which could raise concerns about its long-term viability and operational efficiency.
Recent Developments
Advertisement
Helix BioPharma recently announced a capital raising agreement with Kerentech Consulting Ltd. to support a bridge financing round of USD 13 million. This funding aims to advance its lead therapeutic programs, which could be pivotal for the company's growth trajectory. Additionally, the company closed a private placement of 4,000,000 common shares, raising gross proceeds of CA$3 million.
Market Performance
The stock's 3.16% increase in yesterday's session is a positive indicator for investors, suggesting growing confidence in Helix BioPharma's strategic direction. However, potential investors should be cautious, as the company's recent financial results reported a net loss of CA$5.2 million, highlighting ongoing challenges in achieving profitability.
Looking Ahead
As Helix BioPharma continues to navigate the complexities of the biotech landscape, investors will be keenly watching how effectively the company utilizes its recent capital to drive growth. The upcoming Q3 Investor Summit presentation could provide further insights into the company's plans and performance metrics.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
